Talecris Biotherapeutics Receives FDA Approval For Gamunex®-C

Talecris Biotherapeutics Receives FDA Approval For Gamunex®-C
Talecris Biotherapeutics (Nasdaq: TLCR) announced that the U.S. Food and Drug Administration (FDA) approved Gamunex®-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified) for subcutaneous administration in the treatment of primary immunodeficiency (PI). The newly approved Gamunex-C provides both the intravenous route of administration and a new subcutaneous route of …
Read more on Medical News Today

Gynecologist disputes findings from global study of ovarian cancer
A gynecologic oncologist is warning that the results from a long-awaited global study of ovarian cancer should be viewed cautiously.
Read more on Science Daily

Leading Authority In Cancer Treatment, Research To Chair UF’s Department Of Medicine
An international authority in blood cancers, such as leukemia, lymphoma and myeloma, has been named the new chair of the UF College of Medicine’s department of medicine, according to an announcement Wednesday by Michael Good, M.D., dean of the college. Robert Hromas, M.D., a leader in translating research into the discovery of new cancer drugs, will become chairman of medicine effective Feb. 14 …
Read more on Medical News Today